Comparison · NCT00418938-sae
Panitumumab Plus FOLFIRI vs Bevacizumab Plus FOLFIRI: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Panitumumab Plus FOLFIRI vs Bevacizumab Plus FOLFIRI: serious adverse events. Trial comparisons, record NCT00418938-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00418938-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.459 | 0.376 | 0.543 | wilson | |
| Risk in group 2 | 0.298 | 0.226 | 0.381 | wilson | |
| Risk difference, group 1 minus group 2 | 0.161 | 0.0439 | 0.272 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.54 | 1.12 | 2.12 | log | |
| Odds ratio, group 1 over group 2 | 2 | 1.2 | 3.32 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Panitumumab Plus FOLFIRI than on Bevacizumab Plus FOLFIRI | 6.21 | 3.68 | 22.8 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Panitumumab Plus FOLFIRI | subjects in this arm receive once-every-2-weeks (Q2W) FOLFIRI regimen plus panitumumab 6 mg/kg | 61 | 133 | EG000 |
| Group 2 | Bevacizumab Plus FOLFIRI | subjects in this arm receive once-every-2-weeks (Q2W) FOLFIRI regimen plus bevacizumab (either 5 mg/kg or 10 mg/kg, depending on physician choice and institutional standard of care) | 39 | 131 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- The median reporting period was since randomization date to 65 months.
Source ClinicalTrials.gov
Trial
- Title
- SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
- NCT number
- NCT00418938
- Phases
- PHASE2
- Conditions
- Cancer, Colon Cancer, Colorectal Cancer, Metastatic Cancer, Rectal Cancer, Metastatic Colorectal Cancer
- Interventions
- Panitumumab, Bevacizumab, Leucovorin, Irinotecan, 5-Fluorouracil
- Lead sponsor
- Amgen
- Results first posted
- 2014-03-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00418938?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00418938-sae